Scarica l'app Stockscreener
44.81
3.13%
-1.45
Dopo l'orario di chiusura:
44.81
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - Yahoo Finance
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat
Vera Therapeutics Advances in Autoimmune Treatment - TipRanks
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat
Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times
Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire
Marshall Fordyce Sells 19,375 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics CEO sells shares worth $782,610 By Investing.com - Investing.com South Africa
Vera Therapeutics CEO sells shares worth $782,610 - Investing.com
Trend Tracker for (VERA) - Stock Traders Daily
Markel Corp (MKL-N) QuotePress Release - The Globe and Mail
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):